Needham & Company LLC Reaffirms “Buy” Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a report released on Thursday,Benzinga reports. They currently have a $2.50 target price on the stock. Needham & Company LLC’s target price indicates a potential upside of 153.34% from the company’s current price.

LUCD has been the subject of a number of other research reports. Ascendiant Capital Markets dropped their price target on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating for the company in a research report on Tuesday, September 10th. Canaccord Genuity Group reissued a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group raised Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $3.69.

Lucid Diagnostics Stock Down 2.3 %

NASDAQ:LUCD opened at $0.99 on Thursday. The stock has a market cap of $53.28 million, a PE ratio of -0.87 and a beta of 1.41. The firm’s fifty day simple moving average is $0.87 and its 200-day simple moving average is $0.85. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.58.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC increased its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,671 shares of the company’s stock after buying an additional 13,835 shares during the quarter. Virtu Financial LLC owned about 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the Securities and Exchange Commission. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.